OVID Logo

Ovid Therapeutics Inc. (OVID) 

NASDAQ
Market Cap
$92.26M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
270 of 776
Rank in Industry
157 of 433

Largest Insider Buys in Sector

OVID Stock Price History Chart

OVID Stock Performance

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment …

Insider Activity of Ovid Therapeutics Inc.

Over the last 12 months, insiders at Ovid Therapeutics Inc. have bought $50,364 and sold $0 worth of Ovid Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Ovid Therapeutics Inc. have bought $49,967 and sold $126,203 worth of stock each year.

Highest buying activity among insiders over the last 12 months: LEVIN JEREMY M (CEO) — $50,364.

The last purchase of 18,248 shares for transaction amount of $50,364 was made by LEVIN JEREMY M (CEO) on 2024‑03‑18.

List of Insider Buy and Sell Transactions, Ovid Therapeutics Inc.

2024-03-18PurchaseCEO
18,248
0.0261%
$2.76$50,364-55.31%
2021-07-14SalePresident and CMO
34,017
0.0508%
$3.71$126,203-10.93%
2020-08-28PurchaseCEO
8,488
0.0143%
$5.84$49,570-33.90%
2019-10-08Purchase10 percent owner
2M
4.1699%
$2.50$5M+65.16%
2019-10-08PurchaseCEO
60,000
0.1251%
$2.50$150,000+65.16%
2019-02-26Purchasedirector
10,000
0.0325%
$2.02$20,210+7.32%
2019-02-22PurchaseCEO
75,000
0.2617%
$2.00$150,000+15.34%
2018-08-14Purchasedirector
20,000
0.0386%
$3.12$62,300-60.76%
2018-08-14Purchasedirector
10,000
0.0201%
$3.24$32,442-60.76%
2017-08-25PurchaseCEO
30,668
0.062%
$3.58$109,638+20.31%

Insider Historical Profitability

7.4%
LEVIN JEREMY MCEO
3616715
5.096%
$1.3050+33.6%
TAKEDA PHARMACEUTICAL CO LTD10 percent owner
5750000
8.1018%
$1.3010+65.16%
Bernstein Karendirector
20000
0.0282%
$1.3020<0.0001%
WILLIAMS DOUGLAS Edirector
5000
0.007%
$1.3010<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$18.66M8.626.12M0%+$00.13
Helm Capital Management LLC$16.21M7.495.32M0%+$00.48
BlackRock$12.8M5.914.2M-2.88%-$380,118.44<0.0001
Bvf Inc Il$11.75M5.433.85M-43.75%-$9.14M0.09
Madison Avenue Partners, LP$11.13M5.143.65M0%+$01.82
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.